ARTICLE | Clinical News
Vanda sues FDA over 'unnecessary' dog testing requirement
February 6, 2019 11:23 PM UTC
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) filed suit against FDA requesting a federal court lift a partial clinical hold the agency placed on tradipitant after Vanda refused to conduct a nine-month dog toxicity study.
In an open letter, Vanda called on drug companies to join it in asking FDA to change its policy of routinely requiring "unnecessary" chronic dog studies. "Killing animals without a scientifically justified purpose is unethical and inhumane," it wrote...
BCIQ Company Profiles
BCIQ Target Profiles